Late-stage drug developer Paradigm (ASX:PAR) is trending today after adding a new oral combination IP to its osteoarthritis drug stable. The acquisition came after the company paid $500,000 to buy up Proteobioactives.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
MTM Critical Metals (ASX:MTM) – which has been firming as a new HotCopper forums darling after rocketing +1,387% in a year – was also being heavily discussed after confirming it had raised $50 million through its 55cps placement.
And, VRX Silica Limited (ASX:VRX) popped interest-wise after the WA Minister for Environment determined the Arrowsmith North Silica Sand Project’s EPA was “adequate.”
The ASX 200 at large has gained from open and is up +0.11%.
Join the discussion: See what’s trending right now on Australia’s largest stock forum and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please clickhere.